



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  C08B 37/08, A61K 47/48, 33/24		A1	(11) International Publication Number: <b>WO 96/35720</b>  (43) International Publication Date: 14 November 1996 (14.11.96)
<p>(21) International Application Number: <b>PCT/EP96/01979</b></p> <p>(22) International Filing Date: 8 May 1996 (08.05.96)</p> <p>(30) Priority Data: PD95A000090 10 May 1995 (10.05.95) IT</p> <p>(71) Applicant (<i>for all designated States except US</i>): FIDIA ADVANCED BIOPOLYMERS S.R.L. [IT/IT]; Via de' Carpenteri, 3, I-72100 Brindisi (IT).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): KHAN, Riaz [GB/GB]; "Rumsey" Old Bath Road, Sonning, Berkshire RG4 6TA (GB). KONOWICZ, A., Paul [GB/GB]; 12 Ambleside Crescent, Folly Hill, Farnham, Surrey GU9 0R2 (GB). FLAIBANI, Antonella [IT/IT]; Via Pradamano, 15, I-33100 Udine (IT). GOMBAC, Valentina [IT/IT]; Via Palladio, 3, I-34125 Trieste (IT).</p> <p>(74) Agent: COGGI, Giorgio; Notarbartolo &amp; Gervasi S.r.l., Viale Bianca Maria, 33, I-20122 Milano (IT).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b>  <i>With international search report.</i>  <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> </p>	
<p>(54) Title: HEAVY METAL SALTS OF SUCCINIC ACID HEMIESTERS WITH HYALURONIC ACID, OR HYALURONIC ACID ESTERS, A PROCESS FOR THEIR PREPARATION, AND RELATIVE PHARMACEUTICAL COMPOSITIONS</p> <p>(57) Abstract</p> <p>Hyaluronic acid or hyaluronic acid ester derivatives, wherein one or more hydroxy functions of its 1,4-<math>\beta</math>-D-glucuronic acid and 1,3-<math>\beta</math>-N-acetyl-D-glucosamine alternating repeating units are esterified with a carboxyl group of succinic acid to form the succinic hemiester of hyaluronic acid or hyaluronic acid esters. These derivatives are used to prepare the corresponding heavy metal salts of succinic hemiesters of hyaluronic acid or with hyaluronic acid partial or total esters. These salts are used as active ingredients in the preparation of pharmaceutical compositions to be used as antibacterial and disinfectant agents for the treatment of wounds, burns and ophthalmia or as anti-inflammatory agents in particular for the preparation of pharmaceutical compositions for the treatment of osteoarticular disorders.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

HEAVY METAL SALTS OF SUCCINIC ACID HEMIESTERS WITH HYALURONIC ACID,  
OR HYALURONIC ACID ESTERS, A PROCESS FOR THEIR PREPARATION, AND  
RELATIVE PHARMACEUTICAL COMPOSITIONS

**FIELD OF THE INVENTION**

5 The present invention relates to succinic acid hemiesters with hyaluronic acid or with hyaluronic acid partial or total esters, and heavy metal salts of said succinic hemiesters with hyaluronic acid or hyaluronic acid total or partial esters , a process for their preparation and pharmaceutical compositions containing these salts as  
10 active ingredients.

**BACKGROUND OF THE INVENTION**

Hyaluronic acid is a polysaccharide whose chain is constituted by alternating units of 1,4- $\beta$ -D-glucuronic acid and 1,3- $\beta$ -N-acetyl-D-glucosamine. Hyaluronic acid is a fundamental component of the  
15 connective tissue of animals, being present, for example, in the skin and cartilage. It is also found in high concentrations in the umbilical cord, in the synovial fluid and vitreous humor of the eye. Currently, the preferred source of hyaluronic acid is by extraction from cockscombs, even though the production of hyaluronic acid from  
20 Streptococcus cultures is becoming increasingly widespread (T. J. Lieselang. Survey of Ophthalmology 34, 268-293, 1990).

As hyaluronic acid is a fundamental component of the connective tissue, it is biocompatible, bioadsorbable and not immunogenic. It therefore plays a key role in many biological functions, such as  
25 tissue hydration, the organization of proteoglycans in the cartilage.

- 2 -

tissue repair, embryonic development and lubrication and protection of joint cartilage. This polysaccharide is commonly used in the treatment of some joint diseases, such as rheumatoid arthritis. It is also used in what is known as microviscosurgery, and in particular, in surgery 5 to the eye. In this application, the biocompatibility and rheological characteristics of concentrated solutions of high-molecular-weight hyaluronic acid are exploited.

In cases of inflammation of the joints, hyaluronic acid is degraded by superoxide radicals (Greenwald R. A. et al., Inflammation, 10, 15-30, 10 1986). This degradation determines a notable reduction in the rheological and viscoelastic characteristics of the synovial fluid, markedly reducing the lubricant and protective effect which hyaluronic acid has on the cartilage. It has been hypothesized that the superoxide dismutase enzyme constitutes the main defense against 15 damage caused by the superoxide radical which is produced in the course of inflammatory processes. Copper and zinc are components of the superoxide dismutase enzyme, the function of which seems to be to protect cells from the toxic effects of endogenous superoxide radicals.

20 Rheumatoid arthritis has been associated with zinc deficiencies and an antiinflammatory activity has been hypothesized for zinc itself (A. Frigo et al., "Copper and Zinc in Inflammation", Inflammation and drug therapy series, Vol. IV, Kluwer Academic Publishers, pp. 133-142, 1989). Treatment with zinc sulfate has proved to be efficacious in 25 controlling joint disorders caused by arthritis in patients affected by psoriasis.

In the same way, alterations in copper concentrations have been observed in patients affected by inflammatory diseases in the joints (C. W. Denko, "Copper and Zinc in Inflammation, Inflammation and drug therapy series, Vol. IV, Kluwer Academic Publishers, pp. 1-5, 1989).

5 Copper-based compounds have been used to treat rheumatoid arthritis and their activity is attributed to copper ions.

Gold salts are also used as drugs to treat arthritis, together with known antiinflammatory products of a steroid and non-steroid type (US 4,746,504).

10 Many silver salts, such as silver fluoride, silver iodide, silver lactate, have been used as antibacterial agents for topical use. Their antimicrobial activity is due to the action of the Ag<sup>+</sup> ions.

Heavy metal salts of hyaluronic acid are therefore already known to the state of the art, such as silver, gold, cerium and tungsten. The

15 reaction between a sodium hyaluronate aqueous solution and a silver nitrate solution gives the silver salt of hyaluronic acid. Pharmaceutical preparations containing all these compounds are used to advantage for the treatment of burns, wounds and some ophthalmic infections such as gonococcus-induced conjunctivitis (A. Nimrod and B.

20 Greenman, US Patent No. 4,746,504, May 24, 1988).

However, neither hyaluronic acid nor hyaluronic acid partial or total ester derivatives wherein one or more hydroxy functions of its 1,4 β-D-glucuronic acid and 1,3-β-N-acetyl-D-glucosamine alternating repeating units esterified with a carboxyl group of succinic acid to


25 form the succinic hemiester of hyaluronic acid or hyaluronic acid total or partial esters are known to the state of the art.

- 4 -

#### SUMMARY OF THE INVENTION

The present invention concerns a succinic hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester and its inorganic salt with a heavy metal.

5 In particular the succinic acid hemiester with hyaluronic acid, or with a hyaluronic acid total or partial ester is characterized by having the following repeating unit (I):




(I)

wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> equal or different from each other are H or CO-(CH<sub>2</sub>)<sub>2</sub>-COOY, wherein Y is a negative charge or H, R is OH, O<sup>-</sup> or an 10 alcoholic residue.

The hyaluronic acid esters contemplated for preparing the succinic acid hemiester are the total or partial ester with alcohol of the aliphatic or cycloaliphatic series, which do not themselves possess a notable pharmacological action disclosed in USP 4,851,521, which we 15 incorporate herewith by reference.

- 5 -

The heavy metal salt of the succinic acid hemiester with hyaluronic acid or with a hyaluronic acid total or partial ester are in particular characterized by having the following repeating unit (II):



(II)

wherein  $\text{R}_1$ ,  $\text{R}_2$  and  $\text{R}_3$  equal or different from each other are H or  $\text{COO}^-$   
 5  $(\text{CH}_2)_2\text{COO}^-$ , R is  $\text{O}^-$ , or an alcoholic residue.  $(\text{X}^{z+})$  is a cation of a  
 heavy metal in which z is a number comprised between 1 and 6. p is an  
 integer or a decimal number, comprised between 0.1 and 5 provided that  
 $p(\text{X}^{z+})$  is equal to the number of anionic groups  $\text{COO}^-$  present in said  
 repeating unit. The heavy metal salts according to the pres nt  
 10 invention are characteriz d by having a far greater negative charge  
 density than the corr sponding heavy metal salt of the starting  
 hyaluronate . Indeed, the new substituting group, i.e. succinic acid.

- 6 -

can bind, theoretically, to all the alcoholic functions of the repeating unit, giving a polysaccharide containing up to four succinic groups per repeating unit and therefore four more negative charges available for the formation of salts.

5 A further subject of the present invention relates to the process for preparing said succinic acid hemiester with hyaluronic acid or with a hyaluronic acid partial ester and the corresponding heavy metal salt.

This process in particular comprises the following steps:

10 a) converting the hyaluronic acid sodium salt into a salt selected from the group consisting of pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium salt, in the presence of water and an aprotic solvent,

b) treating the solution coming from step (a) with succinic anhydride

15 in the presence of an organic base, as the catalyst, removing the pyridinium, tetraalkylammonium, tetraarylammonium, tetraalkylphosphonium, or tetraarylphosphonium cation by dialysis, thereby obtaining the succinic acid hemiester having the repeating unit (I) provided that at least one of said repeating units (I) has

20 R = OH or O<sup>-</sup>, and optionally recovering the obtained product by freeze-drying,

c) treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salt of the

25 heavy metal, and recovering the product by filtration and vacuum drying.

- 7 -

In case of the preparation of the heavy metal salt with the succinate hemiester of the total ester of hyaluronic acid, the process according to the present invention contemplates the following steps:

b') treating the hyaluronic acid ester dissolved or suspended in a  
5 mixture of water and an aprotic solvent with succinic anhydride in the presence of an organic base, as the catalyst, thereby obtaining the succinic acid hemiester having the repeating units (I) wherein R is a residue of an alcohol, and optionally recovering the obtained product by freeze-drying.

10 c') treating the solution directly coming from the preceding step or an aqueous solution of the recovered solid product coming from the preceding step with an aqueous solution of an inorganic salt of the heavy metal, and recovering the product by filtration and vacuum drying.

15 The heavy metal salts of succinic acid hemiester with a hyaluronic acid or with a partial or total hyaluronic acid ester according to the present invention can be used to advantage as antimicrobial, antibacterial and disinfectant agents, for the treatment of wounds, burns and ophthalmia, or they can be incorporated in suitable  
20 pharmaceutical forms, optionally in association with one or more other pharmacologically active substances, having a similar therapeutic activity.

In addition they can be advantageously used as disinfectant agents, not only for the preparation of drugs, but also as active ingredients  
25 for the preparation of the so-called health care products, such as cosmetic creams and ointments, shave and after shave lotions and hair lotions etc. or biomaterials such as membranes non-woven tissues,

gauzes, etc.

The heavy metal salts of succinyl monoesters of hyaluronic acid can be also advantageously used as antiinflammatory agents in the treatment of arthritis and inflammations affecting the joints optionally in  
5 association with other pharmaceutically active principles having a similar therapeutical activity.

#### DETAILED DESCRIPTION OF THE INVENTION

The term "heavy metal" encompasses any pharmaceutically active metal in the 4, 5 or 6 period of the periodic table.

10 The preferred heavy metal salts according to the present invention are those whose cation is: zinc, silver, copper, gold, cerium and tungsten salts of succinic derivatives of hyaluronic acid.

It has in fact been found that compared with the corresponding salts with hyaluronic acid or with hyaluronic acid partial esters these  
15 salts offer an advantage over the already-known products containing heavy metal salts, because the salts according to the present invention can bind a high number of heavy metal cations. Indeed, while hyaluronic acid can bind only one counter-ion per repeating unit, the salts according to the present invention bind at least  
20 twice as many counter-ions per repeating unit.

It is therefore advantageous to use these heavy metal salts with higher concentrations of metal for the therapeutic applications identified and described in the text, as this is the most active component in the preparation.

25 Hyaluronic acid or hyaluronic acid esters of any molecular weight can be used to prepare succinyl derivatives thereof. In the present invention, samples of hyaluronic acid with a molecular weight of

between 30,000 and 760,000 Daltons were used, but this range is not critical for the purpose of the present invention.

Preferred succinic acid hemiesters of hyaluronic acid or hyaluronic acid esters are those having in the repeating unit (I)  $R_1 = R_2 = R_3$

5 = H and the corresponding heavy metal salts wherein in the repeating unit (II) X is selected from the group consisting of: silver, gold, copper, zinc, z is comprised between 1 and 3 and p is comprised between 0.3 and 2.

Another class of preferred succinic acid hemiesters with hyaluronic acid or hyaluronic acid esters are those having at least one repeating unit (I) wherein  $R_1 = R_3 = H$  and  $R_2 = CO-(CH_2)_2-COOY$  and at least one repeating unit (I), wherein  $R_2 = R_3 = H$ , and  $R_1 = CO-(CH_2)_2-COOY$  has the above mentioned meanings and the corresponding heavy metal salts have at least one repeating unit (II) wherein  $R_1 = R_3$

10 = H and  $R_2 = CO-(CH_2)_2-COO^-$  and at least one repeating unit (II) wherein  $R_2 = R_3 = H$ ,  $R_1 = CO-(CH_2)_2-COO^-$ , X is selected from the group consisting of: silver, gold, copper, zinc, z is comprised between 1 and 3 and p is comprised between 0.6 and 3.


In the process according to the present invention for preparing the

20 succinic acid hemiesters with hyaluronic acid or with hyaluronic acid partial esters, in step (a) the hyaluronic acid is preferably converted to the corresponding pyridinium salt. In particular this conversion encompasses a previous dissolution of the hyaluronate sodium salt in a mixture of water and dimethylformamide, a treatment

25 with a cationic exchange resin for obtaining the corresponding free hyaluronic acid. After removal of the resin the solution is neutralized with pyridine and the pyridinium salt is thus obtained.

- 10 -

In step (b) or (b') of both processes the amount of succinic anhydride is not critical, although it is preferable to add high excess with respect to hyaluronic acid. In fact the best results are obtained when the molar ratio of succinic anhydride /free OH groups present in the repeating unit (III)



(III)

wherein R has the above mentioned meanings.

of the starting hyaluronic acid or hyaluronic acid partial ester. ranges between 15 and 90. Although the temperature is not critical. the best results are obtained if step (b) or (b') of both processes is carried out at 70°C. The preferred organic base used as catalyst in step (b) or (b') of both processes is selected from the group consisting of 4-dimethylaminopyridine, pyridine, or mixtures thereof.

By using large amounts of 4-dimethylaminopyridine a succinic acid hemiester with hyaluronic acid or a hyaluronic acid ester with a high degree of succinylation is obtained. by using pyridine alone or in admixture with small quantities of 4-dimethylaminopyridine a succinic acid hemiester with hyaluronic acid with a low degree of succinylation

is obtained. Anyway the stronger the reaction conditions, such as temperature, reaction times etc., the greater the degree of esterification of the derivatives formed.

For the preparation of the Ag salt of the succinate hemiester with 5 hyaluronic acid or a hyaluronic acid ester, in step (c) or (c') the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of silver nitrate to form the silver salt of succinate hemiester with hyaluronic acid or hyaluronic acid ester.

10 The Ag salt according to the present invention precipitates from the solution and is recovered by filtration or centrifugation. The precipitate is then washed with ethanol and vacuum dried at 40°C.

The silver compounds of the succinyl derivatives are prepared in the complete dark. All the operations to prepare the silver nitrate 15 solutions, and to prepare the succinyl silver hyaluronate were performed in the dark and the resulting products were stored away from sources of light.

For the preparation of the Cu salts of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c') of 20 both processes, the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of  $CuCl_2$  to form the Cu salt of succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.

25 For the preparation of the Zn salts of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c') of

both processes the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of  $ZnCl_2$  to form the Zn salts of the succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.

For the preparation of the Au salts of the succinate hemiester with hyaluronic acid or a hyaluronic acid ester, in step (c) or (c') of both processes the succinic acid hemiester with hyaluronic acid or the succinic acid hemiester with hyaluronic acid ester is preferably treated with an aqueous solution of  $HAuCl_4$  to form the Au salts of the succinate hemiester with hyaluronic acid or with the hyaluronic acid ester.

The pharmaceutical compositions according to the present invention to be used for the treatment of burns, wounds and ophthalmia preferably contain the Ag salt according to the present invention and are moreover in the form of ointments, creams gels.

The pharmaceutical compositions to be used for the treatment of osteoarticular diseases preferably contain Au, Zn, Cu salts or mixtures thereof.

We report hereafter some specific examples for the preparation of O-succinylhyaluronates and relative heavy metal salts, but any variation not specifically reported in the following examples is to be considered as coming within the scope of the present invention.

- 13 -

Example for the preparation of succinic acid hemiester with  
hyaluronic acid having the repeating unit (I)

Example 1:

A solution of sodium hyaluronate (HA-Na, 1 g, MW 160,000) in distilled  
5 water (35 ml) and N,N-dimethylformamide (DMF, 100 ml) was stirred for  
ten minutes in the presence of ion exchange resin (3 G, IR 120 H +),  
after which the resin was removed by filtration after further dilution  
with DMF (100 ml). The solution was then neutralized with an excess of  
pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py).  
10 The viscous solution was then carefully evaporated in a vacuum to  
remove the water present, taking care not to allow the total volume of  
solution to drop below about 100 ml. This procedure was repeated three  
times, each time adding DMF (20 ml). The solution was then treated  
15 with succinic anhydride (3 g) and pyridine (10 ml) while being stirred  
at room temperature for 24 hours. The reaction mixture was then  
concentrated, gathered with distilled water (20 ml), dialized against  
distilled water (3 times 750 ml) and freeze-dried to give hyaluronic  
acid succinylate (930 mg).

Table 1 shows the assignment of the chemical shift values of the  
20  $^{13}\text{C}$ .n.m.r. (50.3 MHz) spectrum of sample 1.

- 14 -

- TABLE 1 -

Chemical shift in δ ppm	non-modified HA	modified HA	other groups
101.49	N-1		
55.19	N-2		
83.30	N-3		
69.30	N-4		
76.23	N-5		
61.99	N-6		
103.82	G-1		
73.21	G-2		
79.98	G-3		
80.81	G-4		
76.23	G-5		
173.84	G-6		
175.63	N=C=O		
102.50		N-1	
83.00		N-3	
73.85		N-5	
64.08		N-6	
71.74		G-2	
29.79, 29.91			CH <sub>2</sub> succinate
175.35, 177.71			C=O succinate

- 15 -

N.M.R. Analysis shows a degree of succinylation on carbon 6 of the N-acetylglucosamine (N-6) of 0.2 (mol of succinic acid/mol of repeating unit of the polymer).

Example 2:

5 A solution of sodium hyaluronate (HA-Na, 1 g, MW 30,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF, 100 ml) was stirred in the presence of ion exchange resin (3 g, IR 120 H<sup>+</sup>) for 10 minutes and then the resin was removed by filtration after further dilution with DMF (100 ml). The solution was then neutralized with an excess of  
10 pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py). The viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 100 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml). The  
15 solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) while being stirred at 70°C for 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml), dialized against distilled water (3 times 750 ml) and freeze-dried to give hyaluronic acid succinate (900 mg).

20 Table 2 reports the assignment of the chemical shift values of the <sup>13</sup>C;n.m.r. spectrum (50.3 MHz) of sample 2).

- 16 -

- TABLE 2 -

Chemical shift in $\delta$ ppm	non-modified HA	modified HA	other groups
101.77	N-1		
54.33	N-2		
82.91	N-3		
69.93	N-4		
76.31	N-5		
60.95	N-6		
102.77	G-1		
72.58	G-2		
73.88	G-3		
80.94	G-4		
74.13	G-5		
170.00	G-6		
171.83	N=C=O		
102.50		N-1	
83.00		N-3	
73.85		N-5	
63.36		N-6	
70.73		G-2	
28.79			CH <sub>2</sub> succinate
168.98, 173.00			C=O succinate

N.M.R. analysis gives a degree of succinylation on carbon 6 of the Nacetylglucosamine (N-6) of about 0.45 (mol of succinic acid/mol of repeating unit).

Example 3:

5 A solution of sodium hyaluronate (HA-Na, 0.5 g, MW 160,000) in distilled water (35 ml) and N,N-dimethylformamide (DMF 100 ml) was stirred in the presence of ion exchange resin (3 G, IR 120 H<sup>+</sup>) for 10 minutes and then the resin was removed by filtration after further dilution with DMF (75 ml). The solution was then neutralized with an 10 excess of pyridine (6 ml) to give the pyridine salt of hyaluronic acid (HA-Py). the viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 50 ml. This water-removing procedure was repeated three times, each time with the addition of DMF 15 (10 ml). The solution was then treated with succinic anhydride (2 g), 4-dimethylaminopyridine (10 mg) and pyridine (10 ml), while stirring at 70°C for 48 hours. Further quantities of succinic anhydride were added (1 g) and pyridine (2.5 ml) and the mixture was stirred for another 24 hours. The reaction mixture was then concentrated, gathered 20 with distilled water (20 ml), dialized against distilled water (3 times 750 ml) for 3 days and freeze-dried to give hyaluronic acid succinate (450 mg). The product was characterized by a high degree of viscosity when dissolved in water, the n.m.r. spectrum in particular was characterized by wide peaks due to the sample's high 25 degree of viscosity. The degree of modification was assessed by potentiometric assay, and proved to be 1.8 (mol of succinic acid/mol of repeating unit).

Example 4:

A solution of sodium hyaluronate (HA-NA, 0.5 g, MW 240,000) in distilled water (60 ml) and N,N-dimethylformamide (DMF 60 ml) was stirred in the presence of ion exchange resin (1 G, IR 120 H<sup>+</sup>) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml). The solution was then neutralized with an excess of pyridine (6 L) to give the pyridine salt of hyaluronic acid (HA-Py). The viscous solution was then carefully evaporated in a vacuum to remove the water present, without allowing the total volume of the solution to drop below about 100 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml). The gelatin like solution was then treated with succinic anhydride (2 g) and pyridine (5 ml) at 70°C, while being stirred for 18 hours. Further quantities of succinic anhydride (2.5 g) and 4-dimethylaminopyridine (200 mg) were added and the mixture was stirred for another 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml) and freeze-dried to give hyaluronic acid succinylate (450 mg). The product is characterized by being highly viscous when dissolved in water, the n.m.r. spectrum in particular is characterized by very wide peaks due to the highly viscous character of the samples. The degree of modification was assessed by potentiometric assay and the result was 2.5 (mol of succinic acid/mol of repeating unit).

Example 5:

25 A solution of sodium hyaluronate (HA-Na, 1 g, MW 40,000) in distilled water (60 ml) and N,N-dimethylformamide (DMF 60 ml) was stirred in the presence of ion exchange resin (1 g, IR 120 H<sup>+</sup>) for 10 minutes, after

which the resin was removed by filtration after further dilution with DMF (50 ml). The solution was then neutralized with an excess of pyridine (10 ml) to give the pyridine salt of hyaluronic acid (HA-Py). The viscous solution was then carefully evaporated in a vacuum to 5 remove the water present, without allowing the total volume of the solution to drop below 50 ml. This water-removing procedure was repeated three times, each time with the addition of DMF (20 ml). The solution was then treated with succinic anhydride (3 g) and pyridine (10 ml) at 70°C while stirring for 18 hours. Further quantities of 10 succinic anhydride (2.5 g) and 4dimethylaminopyridine (200 mg) were added and the mixture was stirred for another 24 hours. The reaction mixture, which was brown in colour, was then concentrated, gathered with distilled water (20 ml), dialized against distilled water (3 times 750 ml) and freeze-dried to give hyaluronic acid succinylate 15 (850 mg). The degree of succinylation was assessed by potentiometric assay and was 3.5 (mol of succinic acid/mol of repeating unit).

Example 6:

A solution of sodium hyaluronate (HA-Na, 0.5 g, MW 760,000) in distilled water (60 ml) and N,N-dimethylformamide (DMG 60 ml) was 20 stirred in the presence of ion exchange resin (1 g, IR 120 H<sup>+</sup>) for 10 minutes, after which the resin was removed by filtration after further dilution with DMF (50 ml). The solution was then neutralized with an excess of pyridine (6 ml) to give the pyridine salt of hyaluronic acid (HA-Py). The viscous solution was then carefully evaporated to remove 25 the water present, without allowing the total volume of solution to drop below about 50 ml. This procedure was repeated three times, each time with the addition of DMF (20 ml). The gelatin-like solution was

- 20 -

then treated with succinic anhydride (2 g) and 4-dimethylaminopyridine (200 mg) and the mixture was stirred for another 24 hours. The reaction mixture was then concentrated, gathered with distilled water (20 ml), dialized against distilled water (3 times 750 ml) and freeze-  
5 dried to give hyaluronic acid succinylate (430 mg). The product is characterized by being highly viscous when dissolved in water, the n.m.r. spectrum in particular is characterized by very wide peaks due to the highly viscous character of the samples. The degree of modification was assessed by potentiometric assay and was 2.5 (mol of  
10 succinic acid/mol of repeating unit).

Examples of the preparation of silver salts of O-succinyl hyaluronate

Example 7:

100 mg of O-succinyl hyaluronate, prepared as described in Example 1 were dissolved in 10 ml of distilled water. The polymer solution was  
15 then supplemented with 10 ml of a solution of  $\text{AgNO}_3$  1N. The white precipitate thus formed was kept in suspension while being stirred constantly for two hours, and was then gathered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 40°C. All these operations were performed in the  
20 dark to avoid the formation of silver oxide. Atomic absorption analysis showed a silver content of 23.5% in weight, equal to 87% of the theoretical stoichiometric value.

Example 8:

70 mg of hyaluronic acid succinylate, prepared as described in Example 25 3 were dissolved in 14 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 14 ml of a solution of  $\text{AgNO}_3$  1N. A grey precipitate formed immediately and was kept in

suspension while being constantly stirred for two hours, after which it was gathered by filtration through a Buchner funnel. It was washed several times with ethanol and dried in a vacuum oven set at 40°C. All these operations were performed in the dark to avoid the formation of 5 silver oxide. Atomic absorption analysis showed the silver content to be 27% in weight, equal to 71% of the theoretical stoichiometric value.

Example 9:

100 mg of hyaluronic acid succinylate, prepared as described in 10 Example 4, were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of  $\text{AgNO}_3$  2N. A white precipitate formed immediately and was kept in suspension while being constantly stirred for two hours. It was then recovered by filtration through a Buchner funnel, washed 15 several times with ethanol and dried in a vacuum oven set at 40°C. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 28.8% in weight, equal to 70.5% of the theoretical stoichiometric value.

20 Example 10:

100 mg of hyaluronic acid succinylate, prepared as described in Example 5, were dissolved in 10 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 10 ml of a solution of  $\text{AgNO}_3$  1N. A brownish precipitate formed immediately and 25 was kept in suspension while being constantly stirred for two hours, after which it was recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven at 40°C.

- 22 -

All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 31%, equal to 70.2% of the theoretical stoichiometric value.

Example 11:

5 100 mg of hyaluronic acid succinylate, prepared as described in Example 6, were dissolved in 10 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 10 ml of a solution of  $\text{AgNO}_3$  1N. A brownish precipitate was immediately formed, which was kept in suspension while being constantly stirred for two  
10 hours, after which it was recovered by filtration through a Buchner funnel, washed several times with ethanol and dried in a vacuum oven set at 40°C. All these operations were performed in the dark to avoid the formation of silver oxide. Atomic absorption analysis showed the silver content to be 27% in weight, equal to 71% of the theoretical  
15 stoichiometric value.

Examples of the preparation of zinc salts of hyaluronic acid succinylate

Example 12:

100 mg of hyaluronic acid succinylate, prepared as described in  
20 Example 1 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of  $\text{ZnCl}_2$  0.2 N. The solution was stirred constantly for 2 hours, after which 3 volumes of ethanol were added to precipitate the soluble zinc salt. The precipitate was recovered by centrifugation at 3,000 rpm for 15  
25 minutes, washed several times with ethanol and dried in a vacuum oven set at 40°C. Atomic absorption analysis showed a zinc content of 10%, equal to 101% of the theoretical stoichiometric value.

Example 13:

100 mg of hyaluronic acid succinylate prepared as described in Example 3 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of 5  $ZnCl_2$  2 N. After the addition of zinc salt, a powdery precipitate was formed, which was recovered by centrifugation at 3,000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 40°C. Atomic absorption analysis showed the zinc content in the sample to be 15.3%, equal to 105% of the theoretical stoichiometric 10 value.

Example 14:

100 mg of hyaluronic acid succinylate prepared as described in Example 4 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was supplemented with 20 ml of a solution of 15  $ZnCl_2$  2N. After the addition of zinc salt, a powdery precipitate was formed which was recovered by centrifugation at 3,000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 40°C. Atomic absorption analysis showed the zinc content of the sample to be 17.7% in weight, equal to 105% of the theoretical 20 stoichiometric value.

Example of the preparation of the copper salt of hyaluronic acid succinylateExample 15:

100 mg of hyaluronic acid succinylate prepared as described in Example 25 5 were dissolved in 10 ml of distilled water. The polymer solution was then supplemented with 10 ml of a solution of  $CuCl_2$  2N. After the addition of copper salt a blue precipitate was formed which was

recovered by centrifugation at 3,000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven set at 40°C. Atomic absorption analysis showed the copper content of the sample to be 21.4% in weight, equal to 110% of the theoretical stoichiometric 5 value. It is therefore probable that a small amount of copper salt is incorporated by the polymer during precipitation of the derivative.

Example of the preparation of gold salt of hyaluronic acid succinylate


Example 16:

100 mg of hyaluronic acid succinylate prepared as described in Example 10 3 were dissolved in 20 ml of distilled water. The polymer solution, which was highly viscous, was then supplemented with 20 ml of a solution of HAuCL<sub>4</sub> 0.5N. After addition of gold salt, a precipitate was formed which was recovered by centrifugation at 3,000 rpm for 15 minutes, washed several times with ethanol and dried in a vacuum oven 15 at 40°C. The gold content in the sample proved to be 13% in weight, equal to 44% of the theoretical stoichiometric value.

- 25 -

**CLAIMS**

- 1 1. Succinic acid hemiester with hyaluronic acid, or with a hyaluronic acid partial or total ester having the following repeating unit (I):




(I)

- 3 wherein  $R_1$ ,  $R_2$  and  $R_3$  equal or different from each other are H or  $\text{CO}-(\text{CH}_2)_2-\text{COOY}$ , wherein Y is a negative charge or H. R is OH,  $\text{O}^-$  or an alcoholic residue.
- 1 2. The succinic acid hemiester according to claim 1 wherein in the repeating unit (I)  $R_1 = R_2 = R_3 = \text{H}$ .
- 1 3. The succinic acid hemiester according to claim 1 having at least one repeating unit (I) wherein  $R_1 = R_3 = \text{H}$  and  $R_2 = \text{CO}-(\text{CH}_2)_2-\text{COOY}$  and at least one repeating unit (I), wherein  $R_2 = R_3 = \text{H}$ , and  $R_1 = \text{CO}-(\text{CH}_2)_2-\text{COOY}$ .

- 26 -

- 1 4. Heavy metal salt of succinic acid hemiester with hyaluronic acid or
- 2 with a hyaluronic acid total or partial ester, having the following
- 3 repeating unit (II)



(II)

- 4 wherein  $R_1$ ,  $R_2$  and  $R_3$  equal or different from each other are H or  $\text{COO}^-$
- 5  $(\text{CH}_2)_2\text{COO}^-$ , R is  $\text{O}^-$ , or an alcoholic residue,  $(X^{z+})$  is a cation of a
- 6 heavy metal in which z is a number comprised between 1 and 6, p is an
- 7 integer or a decimal number, comprised between 0.1 and 5 provided that
- 8  $p(X^{z+})$  is equal to the number of anionic groups  $\text{COO}^-$  present in said
- 9 repeating unit.

- 1 5. The heavy metal salt according to claim 4 wherein X is selected
- 2 from the group consisting of Ag, Cu, Zn, Au, Ce, W.

- 1 6. The heavy metal salt according to one of claims 4 and 5 wherein
- 2  $R_1 = R_2 = R_3 = \text{H}$ , X is selected from the group consisting of: silver,
- 3 gold, copper, zinc, z is comprised between 1 and 3 and p is comprised
- 4 between 0.3 and 2.


1    7. The heavy metal salt according to one of claims 4,5 and 6, having  
2    at least one repeating unit (II) wherein  $R_1 = R_3 = H$  and  $R_2 = CO-$   
3     $(CH_2)_2-COO^-$  and at least one repeating unit (II) wherein  $R_2 = R_3 = H$ ,  
4     $R_1 = CO-(CH_2)_2-COO^-$ . X is selected from the group consisting of:  
5    silver, gold, copper, zinc. z is comprised between 1 and 3 and p is  
6    comprised between 0.6 and 3.

1    8. A process for preparing the heavy metal salt of succinic acid  
2    hemiester with hyaluronic acid or with a partial ester of hyaluronic  
3    acid according to one of claims 4, 5, 6 and 7 comprising the following  
4    steps:

5    a) converting the hyaluronic acid sodium salt into a salt selected  
6    from the group consisting of pyridinium, tetraalkylammonium,  
7    tetraarylammonium, tetraalkylphosphonium, tetraarylphosphonium salt,  
8    in the presence of water and an aprotic solvent,

9    b) treating the solution coming from step (a) with succinic anhydride  
10   in the presence of an organic base, as the catalyst, removing the  
11   pyridinium                  tetraalkylammonium,                  tetraarylammonium,  
12   tetraalkylphosphonium, or tetraarylphosphonium cation by dialysis  
13   thereby obtaining the succinic acid hemiester with hyaluronic acid or  
14   a partial ester thereof having at least one repeating unit (I)

- 28 -



(I)

15 wherein  $R_1$ ,  $R_2$  and  $R_3$  equal or different from each other are H or  
 16  $CO-(CH_2)_2-COOY$ , wherein Y is a negative charge or H, R is OH,  $O^-$  or an  
 17 alcoholic residue, provided that at least in one repeating unit (I) R  
 18 is OH or  $O^-$

19 and optionally recovering the obtained product by freeze-drying.

20 c) treating the solution directly coming from the preceding step or an  
 21 aqueous solution of the recovered solid product coming from the  
 22 preceding step with an aqueous solution of an inorganic salt of the  
 23 heavy metal, and recovering the product by filtration and vacuum  
 24 drying.

1 9. The process according to claim 8 wherein in step (a) the  
 2 hyaluronic acid is converted to the corresponding pyridinium salt by  
 3 using the following operating conditions:

4 i) dissolving of the hyaluronat sodium salt in a mixture of water  
 5 and dimethylformamide.  
 6 ii) a treatment with a cationic exchange resin to obtain the


- 29 -

7 corresponding free hyaluronic acid.

8 iii) neutralizing the reaction mixture with pyridin thereby  
9 obtaining the pyridinium salt.

1 10. A process for preparing the heavy metal salts of succinic acid  
2 hemiesters with a hyaluronic acid total ester comprising the following  
3 steps:

4 b') treating the hyaluronic acid ester dissolved or suspended in a  
5 mixture of water and an aprotic solvent with succinic anhydride in the  
6 presence of an organic base, thereby obtaining the succinic acid  
7 hemiester having the repeating unit (I)




8 wherein R is a residue of an alcohol, and optionally recovering the  
9 obtained product by freeze-drying.

10 c') treating the solution directly coming from the preceding step or  
11 an aqueous solution of the recovered solid product coming from the  
12 preceding step with an aqueous solution of an inorganic salts of the  
13 heavy metal, and recovering the product by filtration and vacuum  
14 drying.

- 30 -

1 11. The process according to one of claims 8 and 9 or the process  
 2 according to claim 10 wherein step (b) or (b') is carried out by  
 3 using a molar ratio of succinic anhydride /free OH groups present  
 4 in the following repeating unit (III).



(III)

5 of the starting hyaluronic acid or hyaluronic acid partial or total  
 6 ester, which ranges between 15 and 90 and at 70°C and the  
 7 catalyst is selected from the group consisting of 4-  
 8 dimethylaminopyridine, pyridine, or mixtures thereof.

1 12. The process according to one of claims 8, 9 or 11 or the process  
 2 according to one of claims and 10 and 11 for preparing the Ag salts  
 3 of the succinic acid hemiester with hyaluronic acid or a hyaluronic  
 4 acid ester wherein in step (c) or (c') the succinic acid hemiester  
 5 with hyaluronic acid or the succinic acid hemiester with a hyaluronic  
 6 acid total or partial ester is treated with an aqueous solution of  
 7 silver nitrate.

1 13. The process according to one of claims 8, 9 or 11 or the process

2 according to one of claims 10 and 11 for preparing the Zn salts of  
3 the succinic acid hemiester with hyaluronic acid or with a hyaluronic  
4 acid ester wherein in step (c) or (c') the succinic acid hemiester  
5 with hyaluronic acid or with hyaluronic acid total or partial ester is  
6 treated with an aqueous solution of  $ZnCl_2$ .

1 14. The process according to one of claims 8, 9 and 11 or the process  
2 according to one of claims 10 and 11 for preparing the Cu salts of  
3 the succinic acid hemiester with hyaluronic acid or a hyaluronic acid  
4 ester wherein in step (c) or (c') the succinic acid hemiester with  
5 hyaluronic acid or the succinic acid hemiester with hyaluronic acid  
6 ester is treated with an aqueous solution of  $CuCl_2$ .

1 15. The process according to one of claims 8, 9 and 11 or the process  
2 according to one of claims 10 and 11 for preparing the Au salts of  
3 the succinic acid hemiester with hyaluronic acid or a hyaluronic acid  
4 ester wherein in step (c) or (c') the succinic acid hemiester with  
5 hyaluronic acid or the succinic acid hemiester with hyaluronic acid  
6 ester is treated with an aqueous solution of  $HAuCl_4$ .

1 16. A therapeutic composition containing as the active ingredient at  
2 least one heavy metal salt of succinic acid hemiester with hyaluronic  
3 acid or a hyaluronic acid total or partial ester according to one of  
4 claims 4, 5, 6, or 7 optionally in association with other active  
5 ingredients having a similar therapeutical activity.

1 17. The therapeutic composition according to claim 16 for the  
2 treatment of burns, wounds and ophthalmia.

1 18. The therapeutic compositions according to one of claims 16 or 17  
2 in the form of ointments, creams gels.

1 19. The therapeutic compositions according to one of claims 16, 17 or

2 · 18 containing as the active ingredients an Ag salt of a succinic acid  
3 hemiester with hyaluronic acid or a hyaluronic acid total or partial  
4 ester.

1 · 20. The therapeutic compositions according to claim 16 for the  
2 treatment of osteoarticular diseases.

1 · 21. The therapeutic compositions according to one of claims 16 and 20,  
2 containing as the active ingredient at least one heavy metal salt of  
3 succinic acid hemiester with hyaluronic acid or with a hyaluronic acid  
4 ester selected from the group consisting of salts of Au, Cu, and Zn,  
5 or mixtures thereof.

1 · 22. A health care composition containing at least one heavy metal salt  
2 of succinic acid hemiester with hyaluronic acid or a hyaluronic acid  
3 ester according to one of claims 4, 5, 6 or 7.

1 · 23. Biomaterial containing at least one heavy metal salt according to  
2 one of claims 4, 5, 6 or 7.

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 C08B37/0 A61K47/48. A61K33/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C08B A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 314 835 (FAHIM MOSTAFA) 10 May 1989 ---	
A	EP,A,0 066 283 (EUPAN CORPORATION) 8 December 1982 ---	
A	DATABASE WPI Week 7917 Derwent Publications Ltd., London, GB; AN 32582B XP002013867 & JP,A,54 036 388 (SUMITOMO ELEC IND KK) , 17 March 1979 see abstract ---	1
A	US,A,4 746 504 (NIMROD ET AL.) 24 May 1988 cited in the application --- -/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

1 Date of the actual completion of the international search

20 September 1996

Date of mailing of the international search report

02.10.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Lensen, H

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 851 521 (FRANCESCO DELLY VALLE ET AL.) 25 July 1989 cited in the application -----	

Patent document cited in search report	Publication date	Patent family members	Publication date
EP-A-314835	10-05-89	CA-A- 1291034 DE-A- 3778703 US-A- 4711780	22-10-91 04-06-92 08-12-87
EP-A-66283	08-12-82	CA-A- 1181693	29-01-85
US-A-4746504	24-05-88	AU-B- 600483 AU-A- 7206887 CA-A- 1291123 EP-A- 0259485 JP-T- 63502670 US-A- 4784991 WO-A- 8705517	16-08-90 09-10-87 22-10-91 16-03-88 06-10-88 15-11-88 24-09-87
US-A-4851521	25-07-89	AT-T- 135713 AU-B- 591501 AU-A- 5983686 DE-D- 3650501 EP-A- 0216453 EP-A- 0696598 FI-B- 94766 FI-B- 94778 FI-B- 94767 IL-A- 79362 JP-A- 62064802 NO-B- 175716 US-A- 4965353 US-A- 5202431 US-A- 5336767	15-04-96 07-12-89 26-02-87 25-04-96 01-04-87 14-02-96 14-07-95 14-07-95 14-07-95 31-07-95 23-03-87 15-08-94 23-10-90 13-04-93 09-08-94

**THIS PAGE BLANK (USPTO)**